Pharma BD Deal Intelligence
A roughly 400 million dollar bolt-on for an unapproved rare-disease drug became a 5.4 billion dollar per year Pfizer blockbuster franchise.
Full analysis, sources & comparables →Frames the buy as strategically sound: tafamidis, approaching an FDA filing as 'the first disease-modifying agent targeting the underlying cause of a human…
BioPharma Dive flagged tafamidis's $225,000 list price and payer pushback as the central commercial risk to the launch — but acknowledged the FoldRx-acquired…
Pfizer's rare-heart-disease drug Vyndaqel — acquired through the 2010 FoldRx deal — is becoming a blockbuster with $1.3B in 2020 revenue and rapid growth…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Pfizer agreed to acquire privately held FoldRx Pharmaceuticals to gain rare-disease platform anchored by tafamidis, a first-in-class TTR stabilizer. Deal value undisclosed.
A roughly 400 million dollar bolt-on for an unapproved rare-disease drug became a 5.4 billion dollar per year Pfizer blockbuster franchise.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / FoldRx Pharmaceuticals (this deal) | 2010 | — | 99 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
| Pfizer Inc. / Seagen Inc. | 2023 | $43.0B | 77 |
← Browse all deals · How we score deals
More: 2010 deals · Pfizer Inc. deals · Cardiovascular deals